Market Cap | 3.90M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -4.03M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 2.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -47.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -66.00% |
Recommedations | - | Quick Ratio | 0.00 | Shares Outstanding | 406.07M | 52W Low Chg | 3.00% |
Insider Own | 12.22% | ROA | -67.21% | Shares Float | 375.46M | Beta | 0.35 |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.01 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 166,446 | Target Price | - |
Oper. Margin | - | Earnings Date | Jul 12 | Volume | 68,400 | Change | 1.95% |
GB Sciences, Inc., a phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.